Medtronic Percept device against newspaper featuring approval check mark.

FDA Approves Medtronic’s Percept™ PC Deep Brain Stimulation System

The U.S. Food and Drug Administration (FDA) has approved Medtronic’s Percept™ PC Deep Brain Stimulation (DBS) system for the treatment of neurological diseases, such as Parkinson’s disease. Additional conditions approved include:

  • Essential tremor
  • Dystonia
  • Epilepsy
  • Obsessive-compulsive disorder (OCD)

Percept PC DBS uses BrainSense™ technology, making it the first of its kind to both capture and record brain signals while delivering therapy.1

What is deep brain stimulation?

Deep brain stimulation (DBS) uses a small device that sends electronic signals to the area of the brain that controls movement. The signals block some of the abnormal brain messages that occur in some neurological diseases, such as Parkinson’s disease. Blocking these messages help to relieve some of the movement symptoms that occur with Parkinson’s disease.2

Movement symptoms that may improve with the use of DBS include:2

Percept: The first of its kind

The Percept DBS system captures brain signal data directly from the implanted leads in the brain. Doctors can then access this data and adjust the settings as needed. This allows therapy to be unique for every person and promotes the best possible outcomes.3

There are other features to the system that makes it the first of its kind. These features include:

  • A battery that lasts, on average, longer than 5 years before needing to be replaced.
  • Magnetic resonance imaging (MRI) compatibility. This allows for advanced medical imaging that people with previous DBS devices could not access.
  • A programming interface accessed on mobile devices for ease of personalized therapy.
  • Thinner and sleeker design. The Percept PC DBS system is 20 percent thinner than the previous Medtronic DBS system.

Research on Percept

Medtronic has been working with DBS therapy for more than 25 years. Clinical research and trials have been conducted on the efficacy of DBS therapy for numerous neurological diseases, including Parkinson’s. Now that the FDA has approved the Percept PC DBS system, Medtronic plans to conduct further research to determine the safety in adaptive DBS. Adaptive DBS does not continuously stimulate the brain, which may improve clinical outcomes.4,5

How Percept works

The Percept PC DBS system therapy is administered in two phases. The device and all connections are implanted during the surgical phase, and brain recording is turned on. The second phase occurs about one month after surgery. The doctor will program the device for stimulation according to the person’s needs.

During the time between the surgical phase and activation phase, the doctor can monitor the brain waves of the person. This helps to customize the level of stimulation the person needs.6

Availability of Percept

The device was first approved and implanted in people in the European Union. Mayo Clinic in Rochester, Minn., was the first facility in the United States to place the Percept PC DBS system in July 2020.

People who want more information on the device and its availability can contact their doctor for resources on finding a specialist who places the system.

By providing your email address, you are agreeing to our privacy policy. We never sell or share your email address.

This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The ParkinsonsDisease.net team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.

Join the conversation

or create an account to comment.